63590-64-7 Usage
Chemical Properties
White to Off-White Crystalline Powder
Uses
Different sources of media describe the Uses of 63590-64-7 differently. You can refer to the following data:
1. Terazosin is used for the same indications as is prazosin; however, it has the advantage of
being able to be used once a day.
2. An a-1-adrenergicblocker related to prazosin
Clinical Use
Alpha-adrenoceptor blocker:
Hypertension
Benign prostatic hyperplasia (BPH)
Synthesis
Terazosin, 1-(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-(2-tetrahydrofuroyl)-
piperazine (12.2.13), only differs from prazosin in that the furyl radical is replaced with a
tetrahydrofuryl radical. It is synthesized in exactly the same manner except using
1-(2-tetrahydrofuroyl)piperazine instead of 1-(2-furoyl)piperazine [48–51].
Drug interactions
Potentially hazardous interactions with other drugs
Anaesthetics: enhanced hypotensive effect.
Antidepressants: enhanced hypotensive effect with
MAOIs.
Avanafil, vardenafil, sildenafil and tadalafil: enhanced
hypotensive effect - avoid concomitant use.
Beta-blockers: enhanced hypotensive effect;
increased risk of first dose hypotensive effect.
Calcium-channel blockers: enhanced hypotensive
effect; increased risk of first dose hypotensive effect.
Diuretics: enhanced hypotensive effect; increased
risk of first dose hypotensive effect.
Moxisylyte: possibly severe postural hypotension
when used in combination.
Metabolism
Terazosin is metabolised in the liver; one of the
metabolites has antihypertensive activity.
Terazosin is excreted in faeces via the bile, and in the
urine, as unchanged drug and metabolites.
Check Digit Verification of cas no
The CAS Registry Mumber 63590-64-7 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 6,3,5,9 and 0 respectively; the second part has 2 digits, 6 and 4 respectively.
Calculate Digit Verification of CAS Registry Number 63590-64:
(7*6)+(6*3)+(5*5)+(4*9)+(3*0)+(2*6)+(1*4)=137
137 % 10 = 7
So 63590-64-7 is a valid CAS Registry Number.
InChI:InChI=1/C19H25N5O4.ClH.2H2O/c1-26-15-10-12-13(11-16(15)27-2)21-19(22-17(12)20)24-7-5-23(6-8-24)18(25)14-4-3-9-28-14;;;/h10-11,14H,3-9H2,1-2H3,(H2,20,21,22);1H;2*1H2/p-1
63590-64-7Relevant articles and documents
A facile synthesis of [tetrahydrofuran-3H] terazosin
Egan, Judith A.,Souza, Steven M.,Filer, Crist N.
, p. 1881 - 1884 (2004)
An efficient synthesis of [3H] terazosin at high specific activity from prazosin is described.
THERAPY FOR COMPLICATIONS OF DIABETES
-
, (2009/07/02)
A method for enhancing glycemic control and/or insulin sensitivity in a human subject having diabetic nephropathy and/or metabolic syndrome comprises administering to the subject a selective endothelin A (ETA) receptor antagonist in a glycemic control and/or insulin sensitivity enhancing effective amount. A method for treating a complex of comorbidities in an elderly diabetic human subject comprises administering to the subject a selective ETA receptor antagonist in combination or as adjunctive therapy with at least one additional agent that is (i) other than a selective ETA receptor antagonist and (ii) effective in treatment of diabetes and/or at least one of said comorbidities other than hypertension. A therapeutic combination useful in such a method comprises a selective ETA receptor antagonist and at least one antidiabetic, anti-obesity or antidyslipidemic agent other than a selective ETA receptor antagonist.
Process for the preparation of terazosin hydrocloride dihydrate
-
Page/Page column 2; 3-4, (2008/06/13)
The present invention relates to an improved process for the preparation of 1-(4-amino-6,7-dimethoxyquinazolin-2-yl)-4-[[(2RS)-2,3,4,5-tetrahydrofuran-2-yl]carbonyl]piperazine hydrochloride dihydrate of Formula I, through an intermediate 1-(4-amino-6,7-dimethoxyquinazolin-2-yl)-4-[[(2RS)-2,3,4,5-tetrahydrofuran-2-yl]carbonyl]piperazine hydrochloride/hydrobromide (V).
